List of Excipients in Branded Drug BEPREVE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	BEPREVE	bepotastine besilate	24208-629	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	BEPREVE	bepotastine besilate	24208-629	SODIUM CHLORIDE
Bausch & Lomb Incorporated	BEPREVE	bepotastine besilate	24208-629	SODIUM HYDROXIDE
Bausch & Lomb Incorporated	BEPREVE	bepotastine besilate	24208-629	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
Bausch & Lomb Incorporated	BEPREVE	bepotastine besilate	24208-629	WATER
Physicians Total Care Inc	BEPREVE	bepotastine besilate	54868-6299	BENZALKONIUM CHLORIDE

BEPREVE Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

BEPREVE is a preserved ophthalmic solution containing bepotastine besilate equivalent to 1.5% bepotastine. Its excipient system is conventional: benzalkonium chloride for preservation, phosphate salts for buffering, purified water as vehicle, and sodium hydroxide and/or hydrochloric acid for pH adjustment. The main commercial opportunities are preservative-free reformulation, multidose delivery, differentiated tolerability, manufacturing efficiency, and generic substitution rather than novel excipient patenting.[1]

What is BEPREVE and which excipients does it contain?

BEPREVE is indicated for the treatment of itching associated with allergic conjunctivitis. The product is an ophthalmic solution supplied in a multidose container and administered as one drop in each affected eye twice daily.[1]

Attribute	BEPREVE data
Brand name	BEPREVE
Active ingredient	Bepotastine besilate
Active strength	Equivalent to 1.5% bepotastine
Dosage form	Sterile ophthalmic solution
Route	Topical ophthalmic
Indication	Ocular itching associated with allergic conjunctivitis
Dosing	One drop in each affected eye twice daily
Preservative	Benzalkonium chloride, 0.005%
Buffer	Sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate
pH adjustment	Sodium hydroxide and/or hydrochloric acid
Vehicle	Purified water
FDA application	NDA 022134
Regulatory category	Small-molecule drug, not a biologic

The label identifies benzalkonium chloride, or BAK, at 0.005% as the preservative. The phosphate system controls pH, while sodium hydroxide and hydrochloric acid provide final pH adjustment. The labeled pH range is approximately 6.8 to 7.2.[1]

How does the BEPREVE excipient system affect commercial positioning?

The current formula supports a low-cost, conventional multidose product. Its main limitation is BAK exposure. Repeated ophthalmic use of BAK can create a commercial opening for preservative-free or lower-preservative alternatives, especially among patients with chronic allergy, ocular-surface disease, contact-lens use, or concurrent glaucoma therapy.

The excipient strategy has four commercial consequences:

1. BAK enables multidose packaging without a complex dispensing system.
2. Phosphate buffering supports pH control and manufacturing reproducibility.
3. The simple aqueous vehicle limits formulation cost.
4. The absence of a distinctive delivery technology makes differentiation difficult unless a competitor changes preservation, packaging, tolerability, concentration, or dosing frequency.

BEPREVE therefore has a conventional formulation profile rather than a technology-protected delivery platform.

What formulation patents could protect a BEPREVE alternative?

A competitor could seek protection for a new formulation or delivery system, but the commercial value would depend on whether the claims cover clinically meaningful differences from the existing product.

Preservative-free formulations

A preservative-free BEPREVE alternative could use:

• Unit-dose polyethylene ampoules
• Multidose preservative-free pumps
• One-way valve containers
• Filtered dispensing systems
• Container-closure systems that limit microbial ingress

The strongest commercial claims would likely focus on the complete combination of bepotastine, concentration, pH, osmolality, excipient selection, container, and stability profile. A patent directed only to replacing BAK with another known preservative would face greater prior-art exposure.

Alternative preservatives

Potential substitutes include polyquaternium-based systems, oxidative preservatives, stabilized oxychloro complexes, or other ophthalmic antimicrobial systems. Each creates formulation and regulatory risks involving:

• Ocular-surface tolerability
• Preservative effectiveness
• Chemical compatibility with bepotastine
• Container adsorption
• Extractables and leachables
• Stability after opening
• Pediatric and chronic-use suitability

A substitute preservative is not automatically a superior commercial strategy. The product must demonstrate acceptable safety and equivalent or improved performance under FDA ophthalmic standards.

Buffer and tonicity optimization

A phosphate-buffered formulation can be modified through:

• Alternative buffers such as citrate or borate
• Reduced buffer capacity
• Osmolality adjustment
• Reduced ionic strength
• pH optimization for comfort and chemical stability

These changes may support a formulation patent if they produce a documented technical effect, such as improved stability, reduced precipitation, reduced ocular irritation, or improved preservative effectiveness.

What excipient opportunities exist for BEPREVE lifecycle management?

Preservative-free BEPREVE

The clearest lifecycle opportunity is a preservative-free version. A preservative-free product could target patients who use antihistamine drops frequently or have pre-existing ocular-surface sensitivity.

Commercial advantages may include:

• Premium pricing
• Greater acceptance among ophthalmologists
• Differentiation from conventional generic solutions
• Use in patients avoiding BAK
• Potential extension into chronic or recurrent allergic conjunctivitis

The principal disadvantages are higher packaging costs, more complex manufacturing, lower unit economics, and possible reduction in patient convenience if the product requires single-use containers.

Multidose preservative-free delivery

A multidose preservative-free package could combine convenience with an ocular-surface positioning advantage. This approach would be commercially stronger than a standard unit-dose product if the device delivers reliable microbial protection without BAK.

The relevant intellectual property would likely center on the container, valve, pump, closure, formulation-device interaction, and microbial barrier. Device patents may provide more defensible protection than broad excipient claims.

Low-BAK or reduced-exposure formulations

A reduced-BAK strategy could lower preservative exposure while retaining multidose packaging. The commercial case would depend on whether a lower concentration still meets preservative effectiveness requirements and maintains product stability throughout the in-use period.

This strategy may be less differentiated than a fully preservative-free product but could offer lower manufacturing and packaging costs.

Higher-concentration or less-frequent dosing

A formulation enabling once-daily administration could create a stronger commercial proposition than a simple excipient substitution. The development burden would be higher because the sponsor would need to establish dose-response, exposure, ocular tolerability, and clinical efficacy.

A higher-concentration product could also trigger new patent and regulatory issues if it materially changes pharmacokinetics, safety, or clinical use.

How does BEPREVE compare with competing ophthalmic allergy products?

BEPREVE competes with antihistamine and mast-cell stabilizer products, including olopatadine, ketotifen, alcaftadine, and other prescription or over-the-counter ophthalmic products.

Product category	Typical differentiation	Excipient opportunity
Bepotastine ophthalmic solution	Prescription antihistamine therapy	Preservative-free delivery, reduced BAK, improved comfort
Olopatadine ophthalmic products	Broad allergy franchise and multiple concentrations	Packaging, preservative profile, dosing convenience
Ketotifen products	OTC access and low price	Premium preservative-free positioning is more difficult
Alcaftadine products	Once-daily dosing and branded differentiation	Device and tolerability improvements
Mast-cell stabilizer combinations	Allergy prevention and treatment	Buffer, tonicity, and chronic-use tolerability

BEPREVE has less commercial room for a simple me-too formulation than products with larger franchises or multiple approved concentrations. A successful lifecycle product would need to establish a meaningful advantage in comfort, preservation, dosing frequency, container usability, or patient adherence.

What is the FDA regulatory status of BEPREVE?

BEPREVE was approved by the FDA under NDA 022134 for ocular itching associated with allergic conjunctivitis.[1] It is a small-molecule ophthalmic product and does not qualify for biosimilar competition. Generic competitors would generally pursue an abbreviated new drug application, or ANDA, demonstrating pharmaceutical equivalence and bioequivalence or other applicable equivalence standards.

A reformulated BEPREVE product with a materially different excipient system, device, concentration, or dosing regimen could require a new NDA or a supplemental pathway, depending on the extent of the change and the sponsor’s regulatory strategy. FDA guidance treats ophthalmic products as sensitive to formulation, container closure, sterility, particulate matter, preservative effectiveness, and delivery performance.[2]

What is the Orange Book status of BEPREVE?

The Orange Book is the controlling source for approved drug products, therapeutic-equivalence evaluations, and listed patent information.[3] BEPREVE’s practical exclusivity position should be assessed through:

• NDA 022134
• Current Orange Book patent listings
• Patent-use codes
• FDA exclusivity records
• ANDA approval status
• Paragraph IV certifications
• Federal court litigation under the Hatch-Waxman framework

A patent listed for the active ingredient, formulation, or method of use can affect ANDA approval timing. An excipient-focused lifecycle product may avoid direct infringement of a listed patent if its formulation and labeling do not practice the patented claims, but that conclusion requires claim-by-claim analysis.

When does BEPREVE lose exclusivity?

BEPREVE’s commercial exclusivity depends on the surviving patent estate, FDA exclusivity, settlements, and generic approvals. FDA approval alone does not establish the current generic-entry date. The key dates are the earliest expiration of enforceable patents, any pediatric exclusivity extension, and the outcome of Paragraph IV litigation.

Exclusivity issue	Commercial effect
New chemical entity exclusivity	Delays certain ANDA approvals after initial approval
Listed formulation patent	May delay approval if valid and enforceable
Method-of-use patent	Depends on patent scope and approved labeling
Pediatric exclusivity	Can add six months to qualifying exclusivity or patent term
Paragraph IV certification	Can trigger 30-month stay if litigation is timely filed
Patent settlement	May establish an agreed generic-entry date
Unlisted formulation rights	May support litigation or product differentiation but do not necessarily block ANDA approval

No reliable commercial entry forecast should rely on the brand approval date alone. The relevant patent and regulatory records must be reviewed as of the intended launch date.

Which companies could challenge BEPREVE?

Potential challengers include generic ophthalmic manufacturers with sterile liquid capacity, container-closure expertise, and established ANDA operations. The most credible challengers would typically have:

• Sterile ophthalmic filling capability
• BAK-preserved aqueous solution experience
• Access to bepotastine besilate API
• Existing FDA ophthalmic ANDA infrastructure
• Ability to qualify equivalent packaging
• Capacity to manage Paragraph IV litigation

A generic manufacturer could pursue a conventional BAK-preserved solution that closely matches the reference product. A specialty ophthalmic company could instead pursue a preservative-free product under a separate NDA or differentiated regulatory strategy.

What manufacturing and intellectual-property barriers apply?

The active ingredient is not the only barrier. Ophthalmic manufacturing requires validated sterile processing, microbial control, aseptic filling, container-closure integrity, and control of visible and subvisible particles.

The principal technical barriers are:

• API solubility and chemical stability
• Control of pH over shelf life
• Preservative effectiveness
• Sterility assurance
• Container adsorption and leachables
• Drop-size consistency
• In-use stability
• Compatibility with multidose delivery systems
• Scale-up without changes in viscosity or osmolality

The commercial value of an excipient patent increases when it is tied to these measurable manufacturing or performance advantages. A narrow claim covering a known buffer or preservative is less valuable than a claim covering a stable, sterile, preservative-free product delivered through a defined multidose device.

What licensing opportunities exist for BEPREVE excipients or delivery systems?

The most credible licensing opportunities are likely to involve technology platforms rather than individual commodity excipients.

Potential targets include:

• Preservative-free multidose ophthalmic pumps
• Unit-dose filling and packaging technology
• Low-shear sterile filling systems
• Container-closure systems with improved microbial protection
• Novel ophthalmic buffering systems
• Excipient combinations that improve comfort or stability
• Drug-device combinations with protected dispensing performance

Licensing a delivery platform could support multiple ophthalmic allergy products and provide greater return than licensing a single excipient for BEPREVE. A Bepotastine-specific license would need a clear exclusivity position, regulatory advantage, or manufacturing benefit.

What generic launch risks exist for BEPREVE?

A conventional generic could pressure BEPREVE through price competition if it matches the reference product’s strength, route, dosage form, and preservative system. The principal risks are:

1. Early ANDA filing with a Paragraph IV certification.
2. Approval after expiration or settlement of relevant listed patents.
3. Substitution at the pharmacy level.
4. Payer preference for lower-cost generic ophthalmic products.
5. Loss of brand volume before a differentiated reformulation launches.
6. Reduced value of a BAK-preserved brand if physicians shift toward preservative-free products.

BEPREVE’s best defense is a differentiated product with a defensible formulation or delivery patent, supported by evidence of improved tolerability or adherence.

How strong is the BEPREVE patent estate?

The commercial strength of the estate depends less on the original aqueous formulation than on surviving claims directed to specific compositions, concentrations, methods of use, or delivery systems. Conventional excipients such as phosphate buffers, purified water, sodium hydroxide, hydrochloric acid, and BAK are generally weak standalone protection points because they are widely used in ophthalmic products.

A stronger estate would include:

• Narrow but enforceable composition claims
• Clinically relevant preservative-free claims
• Device claims for multidose delivery
• Stability or in-use performance claims
• Method-of-use claims tied to dosing or patient populations
• Continuation or divisional applications with varied claim scope

Key Takeaways

• BEPREVE contains bepotastine besilate in a 1.5% ophthalmic solution.
• Its principal excipients are BAK, phosphate buffers, purified water, sodium hydroxide, and hydrochloric acid.
• BAK is the clearest target for lifecycle reformulation.
• Preservative-free multidose delivery offers the strongest commercial differentiation.
• Commodity excipient substitution alone is unlikely to create durable market protection.
• Device, container-closure, stability, and in-use performance claims may provide stronger intellectual-property value.
• BEPREVE is a small-molecule drug and has no biosimilar pathway.
• Generic risk depends on current Orange Book listings, ANDA activity, Paragraph IV certifications, litigation, and settlements.
• Public revenue exposure for BEPREVE is not separately disclosed in the cited regulatory materials.
• The highest-value licensing opportunities involve ophthalmic delivery platforms that can be used across multiple products.

FAQs About BEPREVE Excipient and Formulation Opportunities

Can BEPREVE be reformulated without benzalkonium chloride?

Yes. A preservative-free BEPREVE product could use unit-dose packaging or a multidose container with microbial-barrier technology. The reformulation would require appropriate stability, sterility, container-closure, and regulatory support.

Is benzalkonium chloride in BEPREVE protected by patent rights?

BAK itself is a widely used ophthalmic preservative and is unlikely to provide meaningful standalone exclusivity for BEPREVE. Any relevant protection would more likely involve the complete formulation, concentration, use, or delivery system.

Could a preservative-free BEPREVE product receive premium pricing?

Yes. Premium pricing is commercially plausible if the product demonstrates improved ocular-surface tolerability, convenient multidose delivery, or a clinically relevant adherence benefit. Packaging costs and payer coverage would determine realized pricing.

Are biosimilars a competitive threat to BEPREVE?

No. BEPREVE contains the small molecule bepotastine besilate. Competition would arise through generic or reformulated ophthalmic products, not biosimilars.

What is the most defensible IP strategy for a BEPREVE successor?

The strongest strategy would combine a defined bepotastine formulation with a protected preservative-free delivery system, demonstrated stability, in-use microbial protection, and clinically supported tolerability or dosing advantages.

References

1. U.S. Food and Drug Administration. (2009). BEPREVE (bepotastine besilate ophthalmic solution) prescribing information. NDA 022134.
2. U.S. Food and Drug Administration. (2016). Quality considerations for topical ophthalmic drug products. Guidance for industry.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files